Figures computed from official regulatory filings — .
Analysttarget 38.5 USD (+1241%) · consensus 5/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 4.12% · institutions 27.13% · short 23.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for NRX Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
23 buys14 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Casper Joseph Michael | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| McBride Dennis | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Javitt Jonathan Ctrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hurvitz Chaimtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Flynn Patrick Johntrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ABRAMS MICHAEL S | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Javitt Jonathan Ctrack record | Buy | $46.8K | conv 51First in 12mo | SEC |
| Gorovitz Aaron | Buy | $11.2K | conv 80ClusterFirst in 12mo | SEC |
| Hurvitz Chaimtrack record | Buy | $20.3K | conv 47Cluster | SEC |
| Javitt Jonathan Ctrack record | Buy | $33K | conv 37 | SEC |
| Javitt Jonathan Ctrack record | Buy | $64K | conv 64First in 12mo | SEC |
| Javitt Jonathan Ctrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| VAN VOORHEES SETHtrack record | Buy | $9.8K | conv 45First in 12mo | SEC |
| VAN VOORHEES SETHtrack record | Buy | $660 | conv 36First in 12mo | SEC |
| Willard Stephen H | Buy | $58.5K | conv 77ClusterFirst in 12mo | SEC |
| VAN VOORHEES SETHtrack record | Buy | $7.8K | conv 55First in 12mo | SEC |
| VAN VOORHEES SETHtrack record | Buy | $33K | conv 58Cluster | SEC |
| Javitt Jonathan Ctrack record | Sell | $400K | Unusual size | SEC |
| Javitt Daniel C. | Sell | $20.6K | SEC |
| Javitt Daniel C. | Sell | $12.7K | SEC |
| Flynn Patrick Johntrack record | Buy | $3.1K | conv 44ClusterFirst in 12mo | SEC |
| Flynn Patrick Johntrack record | Buy | $3.1K | conv 43ClusterFirst in 12mo | SEC |
| Flynn Patrick Johntrack record | Buy | $3.1K | conv 44ClusterFirst in 12mo | SEC |
| Flynn Patrick Johntrack record | Buy | $3.1K | conv 43ClusterFirst in 12mo | SEC |
| Flynn Patrick Johntrack record | Buy | $2.2K | conv 57ClusterFirst in 12mo | SEC |